Orthofix Medical Stock Rises 16% Following CMS Reversal on Bone Growth Stimulators
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: seekingalpha
- Stock Surge: Orthofix Medical (OFIX) shares rose 16% on Monday, primarily driven by CMS's July 1 decision to reverse the final reclassification of non-invasive bone growth stimulators, which is expected to restore prior reimbursement levels and improve the company's financial outlook.
- Analyst Insights: TD Cowen's analyst Matthew Blackman maintains a hold rating on OFIX, noting that CMS's decision allows the company to potentially return to previous reimbursement rates, thereby boosting market confidence in its future performance.
- Market Reaction: Barrington's analyst Michael Petusky rates Orthofix as outperform, stating that the CMS reversal makes sense, although further assessment of reimbursement for bone growth stimulation products remains a possibility, which could impact the company's long-term strategy.
- Future Outlook: While the stock price has surged due to CMS's decision, the market must remain vigilant regarding potential future changes in Medicare policies, which could have profound implications for Orthofix's business model and profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OFIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OFIX
Wall Street analysts forecast OFIX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.720
Low
18.00
Averages
21.33
High
24.00
Current: 11.720
Low
18.00
Averages
21.33
High
24.00
About OFIX
Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Orthofix Medical Stock Rises 16% Following CMS Reversal on Bone Growth Stimulators
- Stock Surge: Orthofix Medical (OFIX) shares rose 16% on Monday, primarily driven by CMS's July 1 decision to reverse the final reclassification of non-invasive bone growth stimulators, which is expected to restore prior reimbursement levels and improve the company's financial outlook.
- Analyst Insights: TD Cowen's analyst Matthew Blackman maintains a hold rating on OFIX, noting that CMS's decision allows the company to potentially return to previous reimbursement rates, thereby boosting market confidence in its future performance.
- Market Reaction: Barrington's analyst Michael Petusky rates Orthofix as outperform, stating that the CMS reversal makes sense, although further assessment of reimbursement for bone growth stimulation products remains a possibility, which could impact the company's long-term strategy.
- Future Outlook: While the stock price has surged due to CMS's decision, the market must remain vigilant regarding potential future changes in Medicare policies, which could have profound implications for Orthofix's business model and profitability.
See More
Innovative Eyewear Reports Significant Q2 Sales Growth
- Significant Sales Growth: Innovative Eyewear Inc. (LUCY) announced preliminary Q2 2026 net sales of approximately $0.99 million, reflecting a 71% year-over-year increase, marking the twelfth consecutive quarter of revenue growth and demonstrating strong performance in the smart eyewear market.
- Retail Partnership Expansion: The company secured an initial purchase order from a Canadian optical retail group operating 345 locations, with product deployment expected to begin in Q3 2026, which will further enhance its market penetration and brand influence.
- Acquisition Proposal Raises Interest: Seer Inc. (SEER) received an unsolicited acquisition proposal from CEO Omid Farokhzad, offering $2.45 per share in cash, with the Board establishing a Special Committee to evaluate the proposal, potentially impacting the company's future strategic direction.
- CMS Policy Reversal Benefits: Orthofix (OFIX) saw a 16% stock increase after CMS withdrew changes to reimbursement policies for non-invasive bone growth stimulators, which is expected to restore reimbursement rates to pre-May 18, 2026 levels, improving the company's financial outlook.
See More
Orthofix Medical Shares Rise 10% After CMS Withdraws Order on Bone Growth Stimulators
- Stock Surge: Orthofix Medical's shares rose approximately 10% in after-hours trading on Thursday, primarily benefiting from CMS's withdrawal of a final order regarding non-invasive bone growth stimulators, which is expected to enhance the company's financial performance.
- CMS Guidance Update: The revised guidance released by CMS on Wednesday indicates that the processing and payment for bone growth stimulators will align with treatment protocols in effect prior to the FDA reclassification, helping the company maintain existing billing requirements and Medicare fee schedules.
- Market Impact: The decision to withdraw the order will prevent negative impacts on Orthofix's billing requirements, thereby safeguarding its revenue streams and potentially strengthening its competitive position in the medical device market.
- Sales Outlook: Despite the Medicare changes, Orthofix reaffirmed its 2026 net sales outlook of $850 million to $860 million while targeting double-digit growth in U.S. limb reconstruction business in the second half of the year.
See More
Orthofix Shares Surge 5.1% Amid Strong Q1 Performance
- Price Surge: Orthofix shares rose 5.1% to $9.78 in the last trading session, with trading volume significantly above average, reflecting investor optimism about the company's future performance.
- Quarterly Results: In Q1 2026, Orthofix reported a loss of $0.52 per share with revenues of $196.7 million, showing a 3.1% year-over-year growth despite the loss, indicating some market demand.
- Future Expectations: The upcoming quarter is expected to see a reduced loss of $0.03 per share, representing a year-over-year decline of 123.1%, suggesting cautious market sentiment regarding the company's future profitability, even as revenue expectations slightly increase.
- Market Watch: Orthofix's consensus EPS estimate has remained unchanged over the past 30 days, indicating a potential lack of upward momentum in the stock price in the short term, prompting investors to closely monitor future earnings estimate revisions.
See More
Halper Sadeh LLC Investigates Orthofix Management for Fiduciary Breaches
- Shareholder Rights Protection: Halper Sadeh LLC is investigating whether certain officers and directors of Orthofix Medical Inc. breached their fiduciary duties, allowing shareholders to consult on legal options at no cost to ensure their rights are protected.
- Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders do not have to bear upfront legal costs, thereby reducing the financial burden of participation in the investigation.
- Opportunity for Governance Reform: Long-term shareholders of Orthofix may seek corporate governance reforms, fund recovery, or court-approved financial incentives, which could enhance the company's transparency and accountability.
- Importance of Shareholder Participation: Active shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, successfully implementing corporate reforms.
See More
Purcell & Lefkowitz Investigates Orthofix Medical for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Orthofix Medical Inc. to determine whether the company's directors breached their fiduciary duties in recent corporate actions, which could impact shareholder rights.
- Shareholder Rights Protection: The investigation focuses on safeguarding the interests of Orthofix Medical's shareholders, ensuring they are informed about their rights and options, reflecting a strong emphasis on corporate governance.
- Legal Consultation Services: Shareholders seeking more information can directly communicate with attorneys through the provided contact details, ensuring they receive professional legal advice at no cost or obligation.
- Firm Background: Purcell & Lefkowitz LLP is dedicated to representing shareholders who are victims of securities fraud and breaches of fiduciary duty, demonstrating its commitment and expertise in protecting investor rights.
See More
Orthofix Medical Stock Rises 16% Following CMS Reversal on Bone Growth Stimulators
- Stock Surge: Orthofix Medical (OFIX) shares rose 16% on Monday, primarily driven by CMS's July 1 decision to reverse the final reclassification of non-invasive bone growth stimulators, which is expected to restore prior reimbursement levels and improve the company's financial outlook.
- Analyst Insights: TD Cowen's analyst Matthew Blackman maintains a hold rating on OFIX, noting that CMS's decision allows the company to potentially return to previous reimbursement rates, thereby boosting market confidence in its future performance.
- Market Reaction: Barrington's analyst Michael Petusky rates Orthofix as outperform, stating that the CMS reversal makes sense, although further assessment of reimbursement for bone growth stimulation products remains a possibility, which could impact the company's long-term strategy.
- Future Outlook: While the stock price has surged due to CMS's decision, the market must remain vigilant regarding potential future changes in Medicare policies, which could have profound implications for Orthofix's business model and profitability.
See More
Innovative Eyewear Reports Significant Q2 Sales Growth
- Significant Sales Growth: Innovative Eyewear Inc. (LUCY) announced preliminary Q2 2026 net sales of approximately $0.99 million, reflecting a 71% year-over-year increase, marking the twelfth consecutive quarter of revenue growth and demonstrating strong performance in the smart eyewear market.
- Retail Partnership Expansion: The company secured an initial purchase order from a Canadian optical retail group operating 345 locations, with product deployment expected to begin in Q3 2026, which will further enhance its market penetration and brand influence.
- Acquisition Proposal Raises Interest: Seer Inc. (SEER) received an unsolicited acquisition proposal from CEO Omid Farokhzad, offering $2.45 per share in cash, with the Board establishing a Special Committee to evaluate the proposal, potentially impacting the company's future strategic direction.
- CMS Policy Reversal Benefits: Orthofix (OFIX) saw a 16% stock increase after CMS withdrew changes to reimbursement policies for non-invasive bone growth stimulators, which is expected to restore reimbursement rates to pre-May 18, 2026 levels, improving the company's financial outlook.
See More
Orthofix Medical Shares Rise 10% After CMS Withdraws Order on Bone Growth Stimulators
- Stock Surge: Orthofix Medical's shares rose approximately 10% in after-hours trading on Thursday, primarily benefiting from CMS's withdrawal of a final order regarding non-invasive bone growth stimulators, which is expected to enhance the company's financial performance.
- CMS Guidance Update: The revised guidance released by CMS on Wednesday indicates that the processing and payment for bone growth stimulators will align with treatment protocols in effect prior to the FDA reclassification, helping the company maintain existing billing requirements and Medicare fee schedules.
- Market Impact: The decision to withdraw the order will prevent negative impacts on Orthofix's billing requirements, thereby safeguarding its revenue streams and potentially strengthening its competitive position in the medical device market.
- Sales Outlook: Despite the Medicare changes, Orthofix reaffirmed its 2026 net sales outlook of $850 million to $860 million while targeting double-digit growth in U.S. limb reconstruction business in the second half of the year.
See More
Orthofix Shares Surge 5.1% Amid Strong Q1 Performance
- Price Surge: Orthofix shares rose 5.1% to $9.78 in the last trading session, with trading volume significantly above average, reflecting investor optimism about the company's future performance.
- Quarterly Results: In Q1 2026, Orthofix reported a loss of $0.52 per share with revenues of $196.7 million, showing a 3.1% year-over-year growth despite the loss, indicating some market demand.
- Future Expectations: The upcoming quarter is expected to see a reduced loss of $0.03 per share, representing a year-over-year decline of 123.1%, suggesting cautious market sentiment regarding the company's future profitability, even as revenue expectations slightly increase.
- Market Watch: Orthofix's consensus EPS estimate has remained unchanged over the past 30 days, indicating a potential lack of upward momentum in the stock price in the short term, prompting investors to closely monitor future earnings estimate revisions.
See More
Halper Sadeh LLC Investigates Orthofix Management for Fiduciary Breaches
- Shareholder Rights Protection: Halper Sadeh LLC is investigating whether certain officers and directors of Orthofix Medical Inc. breached their fiduciary duties, allowing shareholders to consult on legal options at no cost to ensure their rights are protected.
- Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders do not have to bear upfront legal costs, thereby reducing the financial burden of participation in the investigation.
- Opportunity for Governance Reform: Long-term shareholders of Orthofix may seek corporate governance reforms, fund recovery, or court-approved financial incentives, which could enhance the company's transparency and accountability.
- Importance of Shareholder Participation: Active shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, successfully implementing corporate reforms.
See More
Purcell & Lefkowitz Investigates Orthofix Medical for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Orthofix Medical Inc. to determine whether the company's directors breached their fiduciary duties in recent corporate actions, which could impact shareholder rights.
- Shareholder Rights Protection: The investigation focuses on safeguarding the interests of Orthofix Medical's shareholders, ensuring they are informed about their rights and options, reflecting a strong emphasis on corporate governance.
- Legal Consultation Services: Shareholders seeking more information can directly communicate with attorneys through the provided contact details, ensuring they receive professional legal advice at no cost or obligation.
- Firm Background: Purcell & Lefkowitz LLP is dedicated to representing shareholders who are victims of securities fraud and breaches of fiduciary duty, demonstrating its commitment and expertise in protecting investor rights.
See More
